Trusted Resources: Education
Scientific literature and patient education texts
Activity of Daily Living in Mucopolysaccharidosis IVA patients: Evaluation of Therapeutic Efficacy
source: Molecular genetics & genomic medicine
year: 2021
authors: Chen H,Khan S,Celik B,Suzuki Y,Ago Y,Tomatsu S
summary/abstract:Mucopolysaccharidosis IVA (MPS IVA, also called Morquio A syndrome) is caused by a deficiency of N-acetylglucosamine-6-sulfate sulfatase (GALNS) and results in skeletal dysplasia symptoms such as short stature and abnormal gait. Treatments include enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), but the effects are limited depending on the age of initiation and clinical phenotype. Thus, this study aims to assess the effects of treatments on MPS IVA patients compared to untreated MPS IVA patients and an age-matched control group.
organization: University of Delaware, Newark, DE, USA.DOI: 10.1002/mgg3.1806
read more
Related Content
-
Sanfilippo Children’s Foundation – LinkedInSanfilippo Children's Foundation is a no...
-
Increased Choroidal Thickness in Morquio SyndromeThe purpose of this clinical case report...
-
Disease Burden, Management Patterns and Multidisciplinary Clinical Approaches for Patients With MPS IVA and VI in Se...There is a paucity of real-world epidemi...
-
Cervical Disorders in Mucopolysaccharidosis IVA-Morquio DiseaseMorquio disease or mucopolysaccharidosis...
-
Living Through Liminality? Situating the Transitional Experience of Parents of Children With MucopolysaccharidosesMucopolysaccharidoses (MPS) are rare inh...
-
Family Assistance ProgramProgram provides grants of up to $3000 f...
-
Morquio B.ComWe have created this website to bring pe...